MetaCap

BioCardia (BCDA) vs BioStem Technologies (BSEM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioCardia (BCDA) has outperformed BioStem Technologies (BSEM) over the past year, losing 42.7% versus a loss of 84.0%. Over five years, BSEM leads with a -55.9% price change compared with -97.6% for BCDA. BioStem Technologies is the larger company by market cap ($12.2 million vs $11.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BCDA-42.70%BSEM-83.98%
+116%+11%-94%
Nov 21, 20251 yearNov 20, 2026
BCDA-97.64%BSEM-25.28%
+2716%+1242%-232%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BCDA versus BSEM key metrics
MetricBCDABSEM
Share price$0.785$0.6351
Market cap$11.88M$12.18M
1-day change+1.60%-10.23%
YTD return-37.20%-83.33%
1-year return-42.70%-83.98%
5-year return-97.62%-55.90%
P/E ratio (TTM)—0.72
Forward P/E—2.19
EPS (TTM)$-0.51$0.88
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-8.23M—
52-week high$1.80$8.40
52-week low$0.66$0.5347
Distance from 52-week high-56.39%-92.44%
Analyst consensusnonenone
Avg. price target upside+1874.52%+1002.19%
Average volume206.64K194.93K
Shares outstanding15.14M19.18M
Employees1773
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BCDA has outperformed BSEM by 41.3 percentage points over the past year.

About BioCardia

BCDA stock →

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees

About BioStem Technologies

BSEM stock →

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 73 employees

BCDA vs BSEM FAQ

Which is bigger, BioCardia or BioStem Technologies?

BioStem Technologies (BSEM) is larger, with a market capitalization of $12.18M compared with $11.88M for BioCardia (BCDA).

Which stock has performed better over the past year, BCDA or BSEM?

BCDA returned -42.70% over the past 12 months, compared with -83.98% for BSEM (price return, excluding dividends). Past performance does not predict future results.

Are BioCardia and BioStem Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons